NCT00071539 2012-01-20
Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 2 Completed
Teva Branded Pharmaceutical Products R&D, Inc.
Teva Branded Pharmaceutical Products R&D, Inc.